developing selective inhibitors of TYK2 for autoimmune diseases

TARGET

A member of the JAK family, Tyrosine Kinase 2 (TYK2) is a key regulator of both innate and adaptive immunity by mediating type 1 interferon, IL-12 and IL-23 signaling

STRATEGY

Our potent and orally-bioavailable lead molecule is designed as an allosteric inhibitor in order to achieve high selectivity for TYK2 while avoiding inhibition of pan-JAK pathways

OUR TEAM

Our team includes a dedicated group of scientists that have extensive experience in discovering and developing drugs against immunology targets

NEWS / PRESS

Coming soon.

CONTACT